Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect
- Resource Type
- Article
- Source
- In
Gynecologic Oncology June 2020 157(3):578-584 - Subject
- Language
- ISSN
- 0090-8258